Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Perfect opportunity for a simple and quick turnaround test in the aviation industry.
Why aren't IAG buying tests and adding to the price of flights. Test as part of security, the results would be known by boarding time and eliminate any risks. All BA flights could be back in the air next week.
Fair point. In the 5th May GDR RNS, it stated at least 60% gross margin for the covid test. I can’t actually find it in an NCYT RNS but as the gross margin for PrimerDesign for last 2 years has been approx 85%, people are assuming that minus distribution royalties that you are looking at at least 60%.
I never said they were exactly the same products so I will leave that point.
Only real known difference is confirmed orders and known revenue stream. GDR has a great product...need orders now and volumes of sales
why don't you post those RNS's about same gross margins? lazy? but quick to criticise others and demand others for the evidence? Why don't you give a try to show the evidence about "gross margins" and why they are "exactly same products"?
Both companies stated the same predicted gross
margins in RNS’s. Which is all we have to go off.
You used the phrase ‘comparing apples and oranges’ which is used when you think the two things are not valid to compare.
Want to try again?
" Both companies are trying to do pretty much exactly the same. With the same price per test. With the same gross margin."
pretty much exactly the same? Are you saying they are exactly the same? or you are brain is struggling to find the english word "similar"? Both products are not exactly the same for sure.
Also about same gross margin? what calculations have you got to say they have same gross margin? In the past RNS's I haven't seen any cost for manufacturing and the price at which they are planning to sell. Please share your so called 'facts' for the above.
Are you seriously claiming that NCYT can’t be compared to us. Both companies are trying to do pretty much exactly the same. With the same price per test. With the same gross margin.
Again we cannot compare apples and oranges. NCYT and GDR have separate products. Unless we get a RNS about the sales order we cannot say that GDR might not make profits like NCYT.
I doubt it, I'd have to find it again myself. I'm sure it doesn't cost nearly 35 mil per month to produce and distribute eg 5 mil tests at £7. Especially with a good amount staying in the UK.
Yeah Mikesilver i've seen that but i believe that is cost of manufacturing compared to average sale price isnt it? The article I read suggested that the distrubtion and scaling costs were bringing it back to break even for the time being
I read it in an II article, just went looking for it again and most of them look like they have been removed (possibly because incorrect?) considering that there was another article saying the bosses were getting 5 million quid bonuses? Who knows
NCYT are making over 50% on their tests and was published in a previous RNS.
Ben, got the source that says they are barely breaking even? Useful comparison for us.
Isn't this more down the fact that it came out NCYT are barely breaking even on their tests?
Doesn’t help when companies like NCYT post an additional £30m in sales and the share price drops 5%. I know not getting approval in France is unexpected for them but still, a surprising reaction.
Sooner rather than later let’s hope.News from other companies doesn’t help as it gives the impression we are getting left behind and sentiment drops slightly.we just need news to get this moving again and we can hopefully build from strength to strength from there.